RT Journal Article
SR Electronic
T1 Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.14.21263153
DO 10.1101/2021.09.14.21263153
A1 Maroussia Roelens
A1 Alexis Martin
A1 Brian Friker
A1 Filipe Maximiano Sousa
A1 Amaury Thiabaud
A1 Beatriz Vidondo
A1 Valentin Buchter
A1 Céline Gardiol
A1 Jasmin Vonlanthen
A1 Carlo Balmelli
A1 Manuel Battegay
A1 Christoph Berger
A1 Michael Buettcher
A1 Alexia Cusini
A1 Domenica Flury
A1 Ulrich Heininger
A1 Anita Niederer-Loher
A1 Thomas Riedel
A1 Peter W. Schreiber
A1 Rami Sommerstein
A1 Nicolas Troillet
A1 Sarah Tschudin-Sutter
A1 Pauline Vetter
A1 Sara Bernhard-Stirnemann
A1 Natascia Corti
A1 Roman Gaudenz
A1 Jonas Marschall
A1 Yvonne Nussbaumer-Ochsner
A1 Laurence Senn
A1 Danielle Vuichard-Gysin
A1 Petra Zimmermann
A1 Franziska Zucol
A1 Anne Iten
A1 Olivia Keiser
A1 CH-SUR study group
YR 2021
UL http://medrxiv.org/content/early/2021/09/20/2021.09.14.21263153.abstract
AB Background When comparing the periods of time during and after the first wave of the ongoing SARS-CoV-2/COVID-19 pandemic in Europe, the associated COVID-19 mortality seems to have decreased substantially. Various factors could explain this trend, including changes in demographic characteristics of infected persons, and the improvement of case management. To date, no study has been performed to investigate the evolution of COVID-19 in-hospital mortality in Switzerland, while also accounting for risk factors.Methods We investigated the trends in COVID-19 related mortality (in-hospital and in-intermediate/intensive-care) over time in Switzerland, from February 2020 to May 2021, comparing in particular the first and the second wave. We used data from the COVID-19 Hospital-based Surveillance (CH-SUR) database. We performed survival analyses adjusting for well-known risk factors of COVID-19 mortality (age, sex and comorbidities) and accounting for competing risk.Results Our analysis included 16,030 episodes recorded in CH-SUR, with 2,320 reported deaths due to COVID-19 (13.0% of included episodes). We found that overall in-hospital mortality was lower during the second wave of COVID-19 compared to the first wave (HR 0.71, 95% CI 0.69 – 0.72, p-value < 0.001), a decrease apparently not explained by changes in demographic characteristics of patients. In contrast, mortality in intermediate and intensive care significantly increased in the second wave compared to the first wave (HR 1.48, 95% CI 1.42 – 1.55, p-value < 0.001), with significant changes in the course of hospitalisation between the first and the second wave.Conclusion We found that, in Switzerland, COVID-19 mortality decreased among hospitalised persons, whereas it increased among patients admitted to intermediate or intensive care, when comparing the second wave to the first wave. We put our findings in perspective with changes over time in case management, treatment strategy, hospital burden and non-pharmaceutical interventions. Further analyses of the potential effect of virus variants and of vaccination on mortality would be crucial to have a complete overview of COVID-19 mortality trends throughout the different phases of the pandemic.Competing Interest StatementP.W.S. received travel grants from Pfizer and Gilead, honoraries for advisory board activity and talks from Pfizer outside of the submitted work. All other authors declare no conflict of interest.Funding StatementThis work was supported by the Swiss Federal Office of Public Health under reference 333.0-20/1 (UniGe) and 334.0-80/1 (UniBe). O.K. acknowledges additional support from the Swiss National Science Foundation (SNF) via grant #163878. PWS is supported by the academic career program "Filling the Gap" of the Medical Faculty of the University of Zurich.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was submitted and approved by the Geneva Ethics Committee (CCER) and by all hospitals' local Ethics Committees through the Swiss ethics BASEC submission system, under reference 2020-00827.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymised data can be accessed through a multi-stage process described elsewhere [11]. Applicants must fill a concept-sheet and send it to the team in charge of the study. An Executive Committee of experts and representatives of hospital participants will review the concept. Depending on the goal of the analysis, additional ethics clearance might be needed. Data will be restricted to the request and shared through a secure platform.